Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo

Feb 12 2019

• By Emily Hayes

Price cut with sissors and dollar sign

Related Content

Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

Mar 20 2017

PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case

Aug 20 2018

No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor

Feb 01 2019

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

Feb 07 2019

Let's Make A Deal: Sanofi/Regeneron Extend A Hand On Praluent, Express Scripts Takes It

May 01 2018

PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent

Mar 13 2018

Amgen Explains How Big A Hit It May Take From Biosimilars, Pricing Pressures

Jan 30 2019

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Additional Topics

Commercial Pricing Strategies Sales & Earnings Reimbursement Cardiovascular BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window